Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 390

1.

Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.

Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino H, Yamada K, Narui K, Kimura K, Akazawa K, Kohno N; JONIE STUDY GROUP.

Anticancer Res. 2019 Aug;39(8):4305-4314. doi: 10.21873/anticanres.13596.

PMID:
31366522
2.

Parvalbumin-positive GABAergic interneurons deficit in the hippocampus in Gunn rats: A possible hyperbilirubinemia-induced animal model of schizophrenia.

Hayashida M, Miyaoka T, Tsuchie K, Araki T, Izuhara M, Miura S, Kanayama M, Ohtsuki K, Nagahama M, Azis IA, Abdullah RA, Jaya MA, Arauchi R, Hashioka S, Wake R, Tsumori T, Horiguchi J, Oh-Nishi A, Inagaki M.

Heliyon. 2019 Jul 5;5(7):e02037. doi: 10.1016/j.heliyon.2019.e02037. eCollection 2019 Jul.

3.

Electroconvulsive shock restores the decreased coverage of brain blood vessels by astrocytic endfeet and ameliorates depressive-like behavior.

Azis IA, Hashioka S, Tsuchie K, Miyaoka T, Abdullah RA, Limoa E, Arauchi R, Inoue K, Miura S, Izuhara M, Kanayama M, Otsuki K, Nagahama M, Kawano K, Araki T, Hayashida M, Wake R, Oh-Nishi A, Tanra AJ, Horiguchi J, Inagaki M.

J Affect Disord. 2019 Jul 4;257:331-339. doi: 10.1016/j.jad.2019.07.008. [Epub ahead of print]

PMID:
31302522
4.

β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer.

Kurozumi S, Kaira K, Matsumoto H, Hirakata T, Yokobori T, Inoue K, Horiguchi J, Katayama A, Koshi H, Shimizu A, Oyama T, Sloan EK, Kurosumi M, Fujii T, Shirabe K.

Breast Cancer Res Treat. 2019 Jul 9. doi: 10.1007/s10549-019-05341-6. [Epub ahead of print]

PMID:
31290053
5.

The effectiveness of electroconvulsive therapy for psychiatric symptoms and cognitive fluctuations similar to dementia with Lewy bodies: a case report.

Izuhara M, Hashioka S, Sato T, Nishikoori H, Koike M, Matsuda H, Kanayama M, Miura S, Yamashita S, Nagahama M, Otsuki K, Hayashida M, Wake R, Miyaoka T, Inagaki M, Horiguchi J.

Psychogeriatrics. 2019 Jun 4. doi: 10.1111/psyg.12465. [Epub ahead of print] No abstract available.

PMID:
31161654
6.

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.

Kurozumi S, Yamaguchi Y, Matsumoto H, Kurosumi M, Hayashi SI, Fujii T, Horiguchi J, Shirabe K, Inoue K.

PLoS One. 2019 May 21;14(5):e0217279. doi: 10.1371/journal.pone.0217279. eCollection 2019.

7.

Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis.

Kurozumi S, Matsumoto H, Kurosumi M, Inoue K, Fujii T, Horiguchi J, Shirabe K, Oyama T, Kuwano H.

Oncol Lett. 2019 Mar;17(3):2647-2656. doi: 10.3892/ol.2019.9938. Epub 2019 Jan 16.

8.

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.

Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T, Kurosumi M, Shirabe K.

Sci Rep. 2019 Feb 7;9(1):1583. doi: 10.1038/s41598-018-38272-1.

9.

Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling.

Horigome E, Fujieda M, Handa T, Katayama A, Ito M, Ichihara A, Tanaka D, Gombodorj N, Yoshiyama S, Yamane A, Yamada K, Horiguchi J, Shinozuka K, Oyama T, Nishiyama M, Rokudai S.

Oncotarget. 2018 Oct 2;9(77):34554-34566. doi: 10.18632/oncotarget.26177. eCollection 2018 Oct 2.

10.

Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.

Kurozumi S, Yamaguchi Y, Matsumoto H, Inoue K, Kurosumi M, Oyama T, Horiguchi J, Fujii T, Shirabe K.

Med Mol Morphol. 2019 Jun;52(2):90-98. doi: 10.1007/s00795-018-0206-y. Epub 2018 Sep 27.

PMID:
30259117
11.

Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial.

Miyaoka T, Kanayama M, Wake R, Hashioka S, Hayashida M, Nagahama M, Okazaki S, Yamashita S, Miura S, Miki H, Matsuda H, Koike M, Izuhara M, Araki T, Tsuchie K, Azis IA, Arauchi R, Abdullah RA, Oh-Nishi A, Horiguchi J.

Clin Neuropharmacol. 2018 Sep/Oct;41(5):151-155. doi: 10.1097/WNF.0000000000000299.

PMID:
30234616
12.

Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3.

Toda H, Kurozumi S, Kijima Y, Idichi T, Shinden Y, Yamada Y, Arai T, Maemura K, Fujii T, Horiguchi J, Natsugoe S, Seki N.

J Hum Genet. 2018 Dec;63(12):1197-1210. doi: 10.1038/s10038-018-0510-3. Epub 2018 Sep 18.

PMID:
30228364
13.

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.

Kurozumi S, Matsumoto H, Inoue K, Tozuka K, Hayashi Y, Kurosumi M, Oyama T, Fujii T, Horiguchi J, Kuwano H.

PLoS One. 2018 Aug 6;13(8):e0201846. doi: 10.1371/journal.pone.0201846. eCollection 2018.

14.

Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study.

Noguchi E, Tamura K, Hattori M, Horiguchi J, Sato N, Kanatani K, Matsunaga K, Iwata H, Fujiwara Y.

Breast Cancer. 2019 Jan;26(1):39-46. doi: 10.1007/s12282-018-0887-z. Epub 2018 Jul 23.

PMID:
30039339
15.

Gunn rats with glial activation in the hippocampus show prolonged immobility time in the forced swimming test and tail suspension test.

Arauchi R, Hashioka S, Tsuchie K, Miyaoka T, Tsumori T, Limoa E, Azis IA, Oh-Nishi A, Miura S, Otsuki K, Kanayama M, Izuhara M, Nagahama M, Kawano K, Araki T, Liaury K, Abdullah RA, Wake R, Hayashida M, Inoue K, Horiguchi J.

Brain Behav. 2018 Aug;8(8):e01028. doi: 10.1002/brb3.1028. Epub 2018 Jun 28.

16.

Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report.

Izuhara M, Matsuda H, Saito A, Hayashida M, Miura S, Oh-Nishi A, Azis IA, Abdullah RA, Tsuchie K, Araki T, Ryousuke A, Kanayama M, Hashioka S, Wake R, Miyaoka T, Horiguchi J.

Front Psychiatry. 2018 Jun 12;9:260. doi: 10.3389/fpsyt.2018.00260. eCollection 2018.

17.

Salivary Alpha-Amylase Activity Levels in Catatonic Schizophrenia Decrease after Electroconvulsive Therapy.

Kanayama M, Miyaoka T, Araki T, Hayashida M, Hashioka S, Horiguchi J.

Case Rep Psychiatry. 2018 May 10;2018:2623585. doi: 10.1155/2018/2623585. eCollection 2018.

18.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
19.

Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging.

Kaise H, Shimizu F, Akazawa K, Hasegawa Y, Horiguchi J, Miura D, Kohno N, Ishikawa T.

J Surg Res. 2018 May;225:175-180. doi: 10.1016/j.jss.2017.12.002. Epub 2018 Feb 21.

PMID:
29605029
20.

Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).

Fujii T, Horiguchi J, Yanagita Y, Koibuchi Y, Ikeda F, Uchida N, Kimura M; GUNMA BREAST CLINICAL CONFERENCE STUDY GROUP (GBCCSG).

Anticancer Res. 2018 Feb;38(2):905-909.

PMID:
29374719
21.

Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.

Ishikawa T, Akazawa K, Hasegawa Y, Tanino H, Horiguchi J, Miura D, Hayashi M, Kohno N.

J Surg Res. 2017 Dec;220:46-51. doi: 10.1016/j.jss.2017.05.066. Epub 2017 Jul 26.

PMID:
29180210
22.

Remission of Psychosis in Treatment-Resistant Schizophrenia following Bone Marrow Transplantation: A Case Report.

Miyaoka T, Wake R, Hashioka S, Hayashida M, Oh-Nishi A, Azis IA, Izuhara M, Tsuchie K, Araki T, Arauchi R, Abdullah RA, Horiguchi J.

Front Psychiatry. 2017 Sep 21;8:174. doi: 10.3389/fpsyt.2017.00174. eCollection 2017.

23.

Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.

Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, Kuwano H.

Med Mol Morphol. 2017 Dec;50(4):185-194. doi: 10.1007/s00795-017-0170-y. Epub 2017 Sep 21. Review.

PMID:
28936553
24.

Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients.

Obayashi S, Horiguchi J, Higuchi T, Katayama A, Handa T, Altan B, Bai T, Bao P, Bao H, Yokobori T, Nishiyama M, Oyama T, Kuwano H.

Int J Oncol. 2017 Sep;51(3):781-790. doi: 10.3892/ijo.2017.4085. Epub 2017 Jul 27.

25.

Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome.

Katayama A, Handa T, Komatsu K, Togo M, Horiguchi J, Nishiyama M, Oyama T.

Pathol Int. 2017 Aug;67(8):404-413. doi: 10.1111/pin.12560. Epub 2017 Jul 11.

PMID:
28699235
26.

Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients.

Handa T, Katayama A, Yokobori T, Yamane A, Horiguchi J, Kawabata-Iwakawa R, Rokudai S, Bao P, Gombodorj N, Altan B, Kaira K, Asao T, Kuwano H, Nishiyama M, Oyama T.

J Surg Oncol. 2017 Nov;116(6):706-715. doi: 10.1002/jso.24705. Epub 2017 Jun 1.

PMID:
28570747
27.

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.

Kurozumi S, Matsumoto H, Hayashi Y, Tozuka K, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Kurosumi M.

BMC Cancer. 2017 May 22;17(1):354. doi: 10.1186/s12885-017-3331-4.

28.

Myeloid sarcoma arising in malignant phyllodes tumour: clonal relationships revealed by comparative genome-wide analyses.

Arai H, Nobusawa S, Kawabata-Iwakawa R, Rokudai S, Higuchi T, Yamazaki T, Horiguchi J, Sano T, Kojima M, Nishiyama M, Yokoo H, Hirato J, Oyama T.

Br J Haematol. 2018 Apr;181(2):255-259. doi: 10.1111/bjh.14539. Epub 2017 Feb 17. No abstract available.

PMID:
28211578
29.

Prognostic Significance of the Expression of CD98 (4F2hc) in Gastric Cancer.

Satoh T, Kaira K, Takahashi K, Takahashi N, Kanai Y, Asao T, Horiguchi J, Oyama T.

Anticancer Res. 2017 Feb;37(2):631-636. Erratum in: Anticancer Res. 2017 Mar;37(3):1539.

PMID:
28179310
30.

Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.

Fujii T, Yajima R, Kurozumi S, Higuchi T, Obayashi S, Tokiniwa H, Nagaoka R, Takata D, Horiguchi J, Kuwano H.

Anticancer Res. 2016 Oct;36(10):5481-5485.

PMID:
27798919
31.

Successful management of perioperative hemostasis in a patient with Glanzmann thrombasthenia who underwent a right total mastectomy.

Ogawa Y, Kunishima S, Yanagisawa K, Osaki Y, Uchiyama Y, Matsumoto N, Tokiniwa H, Horiguchi J, Nojima Y, Handa H.

Int J Hematol. 2017 Feb;105(2):221-225. doi: 10.1007/s12185-016-2096-x. Epub 2016 Oct 1.

PMID:
27696190
32.

Characteristics of Japanese aldosterone-producing adenomas with KCNJ5 mutations.

Okamura T, Nakajima Y, Katano-Toki A, Horiguchi K, Matsumoto S, Yoshino S, Yamada E, Tomaru T, Ishii S, Saito T, Ozawa A, Shibusawa N, Satoh T, Okada S, Nagaoka R, Takada D, Horiguchi J, Oyama T, Yamada M.

Endocr J. 2017 Jan 30;64(1):39-47. doi: 10.1507/endocrj.EJ16-0243. Epub 2016 Sep 28.

33.

Vascular network tightly enclosing lesions of molluscum contagiosum: Basket-like capillaries of molluscum.

Horiguchi Y, Horiguchi J, Maeno KI.

J Dermatol. 2017 Jan;44(1):52-58. doi: 10.1111/1346-8138.13519. Epub 2016 Sep 8.

PMID:
27607603
34.

Electroconvulsive shock attenuated microgliosis and astrogliosis in the hippocampus and ameliorated schizophrenia-like behavior of Gunn rat.

Limoa E, Hashioka S, Miyaoka T, Tsuchie K, Arauchi R, Azis IA, Wake R, Hayashida M, Araki T, Furuya M, Liaury K, Tanra AJ, Horiguchi J.

J Neuroinflammation. 2016 Sep 2;13(1):230. doi: 10.1186/s12974-016-0688-2.

35.

[LEVEL Ⅲ LYMPH NODE DISSECTION FOR BREAST CANCER].

Horiguchi J.

Nihon Geka Gakkai Zasshi. 2016 Sep;117(5):412-4. Japanese. No abstract available.

PMID:
30169006
36.

Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J.

J Hum Genet. 2017 Jan;62(1):15-24. doi: 10.1038/jhg.2016.89. Epub 2016 Jul 21. Review.

PMID:
27439682
37.

A Long-term Study of the Association between the Relative Poverty Rate and Suicide Rate in Japan.

Inoue K, Fujita Y, Takeshita H, Abe S, Fujihara J, Ezoe S, Sampei M, Miyaoka T, Horiguchi J, Okazaki Y, Fukunaga T.

J Forensic Sci. 2016 Jan;61 Suppl 1:S140-3. doi: 10.1111/1556-4029.12998. Epub 2015 Dec 22.

PMID:
27405019
38.

Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer.

Kurozumi S, Yamaguchi Y, Hayashi S, Hiyoshi H, Suda T, Gohno T, Matsumoto H, Takei H, Horiguchi J, Takeyoshi I, Oyama T, Kurosumi M.

Cancer Med. 2016 Aug;5(8):1873-82. doi: 10.1002/cam4.780. Epub 2016 Jun 23.

39.

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.

Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Ranger-Moore J, Allred DC, Dennis E, Nitta H.

Breast Cancer Res Treat. 2016 Jul;158(1):99-111. doi: 10.1007/s10549-016-3856-2. Epub 2016 Jun 18.

40.

Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET.

Fujii T, Yajima R, Tsuboi M, Higuchi T, Obayashi S, Tokiniwa H, Nagaoka R, Takata D, Horiguchi J, Kuwano H.

Anticancer Res. 2016 Jun;36(6):3019-22.

PMID:
27272820
41.

Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.

Higuchi T, Endo M, Hanamura T, Gohno T, Niwa T, Yamaguchi Y, Horiguchi J, Hayashi S.

PLoS One. 2016 May 26;11(5):e0155844. doi: 10.1371/journal.pone.0155844. eCollection 2016.

42.

Aceruloplasminemia With Psychomotor Excitement and Neurological Sign Was Improved by Minocycline (Case Report).

Hayashida M, Hashioka S, Miki H, Nagahama M, Wake R, Miyaoka T, Horiguchi J.

Medicine (Baltimore). 2016 May;95(19):e3594. doi: 10.1097/MD.0000000000003594.

43.

Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder.

Wake R, Miyaoka T, Furuya M, Hashioka S, Horiguchi J.

CNS Neurol Disord Drug Targets. 2016;15(5):551-63. Review.

PMID:
27071791
44.

Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.

Tanaka K, Shimizu K, Kakegawa S, Ohtaki Y, Nagashima T, Kaira K, Horiguchi J, Oyama T, Takeyoshi I.

Am J Transl Res. 2016 Jan 15;8(1):81-97. eCollection 2016.

45.

GNAS mutations in adrenal aldosterone-producing adenomas.

Nakajima Y, Okamura T, Horiguchi K, Gohko T, Miyamoto T, Satoh T, Ozawa A, Ishii S, Yamada E, Hashimoto K, Okada S, Takata D, Horiguchi J, Yamada M.

Endocr J. 2016;63(2):199-204. doi: 10.1507/endocrj.EJ15-0642. Epub 2016 Jan 6.

46.

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).

Hasegawa Y, Tanino H, Horiguchi J, Miura D, Ishikawa T, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Akazawa K, Kohno N; JONIE Study Group.

PLoS One. 2015 Dec 3;10(12):e0143643. doi: 10.1371/journal.pone.0143643. eCollection 2015.

47.

APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.

Tsuboi M, Yamane A, Horiguchi J, Yokobori T, Kawabata-Iwakawa R, Yoshiyama S, Rokudai S, Odawara H, Tokiniwa H, Oyama T, Takeyoshi I, Nishiyama M.

Breast Cancer. 2016 Sep;23(5):780-8. doi: 10.1007/s12282-015-0641-8. Epub 2015 Oct 17.

PMID:
26476745
49.

Can inhibition of microglial activation cure schizophrenia?

Hashioka S, McGeer PL, Miyaoka T, Wake R, Horiguchi J.

Schizophr Res. 2015 Oct;168(1-2):583-4. doi: 10.1016/j.schres.2015.07.042. Epub 2015 Aug 4. No abstract available.

PMID:
26254144
50.

Ramelteon as adjunctive therapy for delirium referred to a consultation-liaison psychiatry service: a retrospective analysis.

Furuya M, Miyaoka T, Yasuda H, Wake R, Hashioka S, Miura S, Nagahama M, Araki T, Horiguchi J.

Int J Geriatr Psychiatry. 2015 Sep;30(9):994-5. doi: 10.1002/gps.4280. No abstract available.

PMID:
26220878

Supplemental Content

Loading ...
Support Center